Chris Varma, Frontier Medicines CEO
February 22, 2024 04:01 PM ESTUpdated February 23, 05:56 PM
Financing
Startups

Fron­tier Med­i­cines rais­es $80M, en­ters clin­ic and eyes po­ten­tial IPO in Q4 or ear­ly 2025

Kyle LaHucik

Senior Reporter

Fron­tier Med­i­cines, a bi­coastal biotech cre­at­ing co­va­lent small mol­e­cules, has se­cured $80 mil­lion in Se­ries C funds and dosed the first pa­tient in its ini­tial …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

Ma­jor PBM re­forms fea­ture in Con­gress' year-end spend­ing bill

What Trump’s FTC picks mean for bio­phar­ma deal­mak­ing and PBMs

Up­dat­ed: Ver­tex’s non-opi­oid pill dis­ap­points in mid-stage chron­ic pain study

A service from the Financial Times